Valeant Pharmaceuticals (NYSE: VRX) shares soared this week after hedge-fund manager John Paulson joined its board, and reports emerged out of Washington, D.C. suggesting that President Donald Trump may embrace industry-friendly drug price reforms.Paulson is no stranger to Valeant Pharmaceuticals. In fact, he became the company's biggest shareholder after fellow hedge fund manager Bill Ackman threw in the towel on Valeant Pharmaceuticals earlier this year.Image source: Getty Images.Continue reading